Perilla for Health & Longevity - Quick Reference Sheet

Perilla for Health & Longevity

Created on 10/17/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Perilla is an East Asian herb used in two oral preparations, plant omega-3 seed oil and antioxidant leaf extract, for seasonal allergies, digestive comfort, and longevity. Moderate human evidence supports relieving nasal and eye allergies, bloating, constipation, and mild knee pain, and preserving heel bone density, whereas cholesterol, cognitive, blood pressure, mood, and blood-clotting findings are conflicted. Studied doses show placebo-like adverse-event rates, though severe seed allergies occur. (Full Review)

Protocol

Seed oil protocol
3.0–4.8 g/day or 7.0 mL/day
3.0 g/day for diabetic dyslipidemia, 4.0 g/day in dementia, 4.8 g/day for platelets, or 7.0 mL/day for BMD (3–9 g/day in female athletes); administered orally once or split twice daily (1.5–3.5 g/dose)
Leaf extract protocol
50–1,400 mg/day
1,400 mg/day for knee pain, 500 mg/day for cognition, 300 mg/day for gut, or 50–200 mg/day for allergy (or 9.0 g/day dried whole-leaf powder alternative for Ox-LDL and prehypertensive SBP)
Time of day
With meals (oil); 30–60 min pre-meal (extract)
Seed oil administered orally with fat-containing morning and evening meals; aqueous leaf extract split twice daily 30–60 minutes before breakfast and dinner
Time to effect
Gastrointestinal Comfort, Bowel Regularity, and Gut Microbiota Modulation
3–28 days (leaf); 8 weeks (oil)
Bloating and abdominal discomfort improve within 3–28 days (4 weeks) at 300 mg/day leaf extract (allergic rhinoconjunctivitis also improves within 3–28 days); constipation and gut microbiota improve over 8 weeks at 3–9 g/day seed oil
Knee Joint Pain and Functional Mobility Improvement
8 weeks
Knee pain VAS and WOMAC functional mobility scores improve over 8 weeks at 1,400 mg/day leaf extract (early cognitive scores shift by 12 weeks at 500 mg/day leaf extract)
Bone Mineral Density Preservation
6–12 months
Calcaneal bone mineral density (%YAM) and serum TRACP-5b improve after 12 months at 7.0 mL/day seed oil (lipid and prehypertensive blood pressure changes take 6 months)

Benefits

Contraindications
  • Individuals with confirmed IgE-mediated perilla seed allergy
  • Individuals with documented allergic contact dermatitis to perilla leaf monoterpenes such as perillaldehyde or perillalcohol
  • Individuals with liver, renal, cardiovascular, or gastrointestinal disease, pregnant or lactating women, or those taking antiplatelet or lipid-altering medications
Key Interactions
  • Anticoagulant and antiplatelet drugs (warfarin, apixaban, clopidogrel): Monitor (theoretical)
  • Cytochrome P450 3A4 (CYP3A4, a major drug-metabolizing liver enzyme) substrates (tacrolimus, midazolam, atorvastatin): Caution (theoretical)
  • Over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs, pain relievers such as aspirin, ibuprofen, naproxen): Monitor (theoretical)
  • Over-the-counter histamine-1 receptor (H1, allergy histamine receptor) antihistamines (cetirizine, loratadine, fexofenadine): Low-risk additive
  • Omega-3 and antiplatelet supplements (fish oil, krill oil, Ginkgo biloba, garlic): Caution (theoretical)
  • Antihypertensive supplements (coenzyme Q10, aged garlic extract, hibiscus): Monitor (theoretical, SBP ≥ 120 mmHg)
  • Standardized Citrus reticulata (ponkan) or Anredera cordifolia leaf powders: Synergistic co-intervention

Risk & Side Effects

  • High:
  • Medium:
  • Low: Immediate Seed and Leaf Allergic Reactions; Allergic Contact Dermatitis; Mild Gastrointestinal Disturbances
  • Speculative: Pulmonary Toxicity from Perilla Ketone Chemotypes; High-Dose Perillaldehyde Hepatotoxicity and Genotoxicity

Monitoring

Marker Target Why
Serum LDL-C and ApoB No established target; reduction from individual baseline Efficacy marker: perilla seed oil (3 g/day) significantly lowers LDL-C and ApoB (fasted at baseline, 12 weeks, and 6 months)
Erythrocyte ALA and EPA (%) No established target; increase from individual baseline Efficacy marker: confirms absorption and elongation of seed oil ALA via red blood cell gas chromatography (baseline and 8–12 weeks)
Serum TRACP-5b 170–590 mU/dL in men; 120–420 mU/dL in premenopausal women; 250–760 mU/dL in postmenopausal women (standard reference range) Efficacy marker: 12-month seed oil intake lowers bone resorption (morning fasted serum, paired with annual calcaneal ultrasound bone densitometry %YAM)
Collagen-ADP Closure Time (PFA-100) 62–100 seconds (standard reference range) Safety and efficacy check: 4.8 g/day seed oil prolongs closure time (baseline and 8 weeks if co-administered with antiplatelet or anticoagulant agents)
Perilla Seed Allergy Testing No established target; qualitative absence of sensitization Safety check: rules out IgE sensitization before use in seed-allergic individuals via specialist allergy workups (no commercial standardized assay exists)

Cadence: Baseline fasted blood panels and specialist allergy evaluation (in seed-allergic individuals) before initiation; re-evaluation at 4 weeks (tolerability and gastrointestinal comfort), 8–12 weeks (erythrocyte fatty-acid incorporation, lipids, and platelet closure time), and every 6–12 months thereafter (sustained cardiometabolic and annual calcaneal %YAM / TRACP-5b skeletal preservation).

Qualitative Assessment

  • Bloating and stool regularity: Weekly digestive logs
  • Nasal and ocular symptoms: Daily allergy scores
  • Easy bruising: Ongoing bleeding-tendency check